Thalidomide, an antiangiogenic agent with clinical activity in cancer

被引：21
|
作者：
Ng, SSW [1 ]
Brown, M [1 ]
Figg, WD [1 ]
机构：
[1] Natl Canc Inst, Mol Pharmacol Sect, Canc Therapeut Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2002年 / 56卷 / 04期
关键词：
thalidomide; HIV-infection; bFGF; VEGF;
D O I：
10.1016/S0753-3322(02)00177-4
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Despite the teratogenic past of thalidomide, there is recent evidence indicating the drug's efficacy in the management of various diseases from immune disorders to cancers. The history, pharmacodynamic and pharmacokinetic properties of thalidomide in the clinic are discussed in this review article. (C) 2002 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码：194 / 199
页数：6
相关论文
共 50 条
  • [21] Thalidomide: an effective anabolic agent in gastrointestinal cancer cachexia
    Wilkes, EA
    Freeman, JG
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (03) : 445 - 446
  • [22] Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives
    Sievers, Johannes
    Voget, Rabea
    Lu, Feiteng
    Garchitorena, Kathleen M.
    Ng, Yuen Lam Dora
    Chau, Cindy H.
    Steinebach, Christian
    Figg, William D.
    Kronke, Jan
    Guetschow, Michael
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 110
  • [23] Thalidomide metabolites and analogs, part 3:: Synthesis and antiangiogenic activity of the teratogenic and TNF-α-modulatory thalidomide analog EM-12.
    Luzzio, FA
    Figg, WD
    Mayorov, AV
    Kruger, EA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U685 - U685
  • [24] Antiangiogenic agent synthesized
    不详
    CHEMICAL & ENGINEERING NEWS, 2008, 86 (21) : 37 - 37
  • [25] Antiangiogenic therapy of cancer: Experimental and clinical studies
    Folkman, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R371 - R371
  • [26] ANTITUMOR AND ANTIANGIOGENIC ACTIVITY OF SORAFENIB ON COLORECTAL CANCER
    Kilickap, S.
    Altun, A.
    Babacan, N. A.
    Ataseven, H.
    Kaya, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 220 - 220
  • [27] Clinical experience with antiangiogenic targeting in ovarian cancer
    Bookman, M. A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 50 - 50
  • [28] Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy
    Behl, Tapan
    Kaur, Ishneet
    Goel, Heena
    Kotwani, Anita
    VASCULAR PHARMACOLOGY, 2017, 92 : 6 - 15
  • [29] A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
    Rajkumar, SV
    Witzig, TE
    CANCER TREATMENT REVIEWS, 2000, 26 (05) : 351 - 362
  • [30] Thalidomide. Clinical trials in cancer.
    Politi, PM
    MEDICINA-BUENOS AIRES, 2000, 60 : 61 - 65
12345